← Back to Search

Other

TL-895 + Navtemadlin for Chronic Lymphocytic Leukemia

Phase 1 & 2

Waitlist Available

Research Sponsored by Telios Pharma, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Treatment naïve CLL or SLL for Arm 3, 4, and 6

ECOG performance status of ≤ 2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline up to end of study (2 years after last patient enrolled)

Awards & highlights

Study Summary

This trial is testing a new drug, TL-895, to see if it is safe and tolerable for people with relapsed or refractory B cell malignancies who have failed one to three prior therapies. The trial has two parts; the first part has already completed testing and the second part is currently enrolling participants. The second part of the trial will test different doses of TL-895 on two groups of people: those who have failed at least one prior therapy, and those who have not received any prior therapy. Every participant in the study will receive TL-895.

Who is the study for?

This trial is for adults with certain types of blood cancers like CLL or SLL who have either not been treated before (treatment naïve) or whose disease came back after treatment (relapsed/refractory). They should be relatively active and able to care for themselves, with their major organs working well. Pregnant women, breastfeeding mothers, those who've had organ transplants, or previous treatments with BTK/PI3K inhibitors can't join.Check my eligibility

What is being tested?

The study tests the safety and best dose of a drug called TL-895 alone and in combination with Navtemadlin. Participants are randomly assigned to receive different doses of TL-895 twice daily. Some will also get Navtemadlin once daily if they haven't responded to prior therapies or if they're new patients without a specific genetic change (17p deletion).See study design

What are the potential side effects?

Specific side effects aren't listed here but generally could include issues related to how the body tolerates the drugs such as nausea, fatigue, allergic reactions, liver problems, changes in blood counts leading to increased infection risk or bleeding tendencies.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have not received any treatment for my CLL or SLL.

Select...

I can take care of myself but might not be able to do heavy physical work.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline up to end of study (2 years after last patient enrolled)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline up to end of study (2 years after last patient enrolled)

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to end of study (2 years after last patient enrolled) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Part 1 (Dose Escalation): DLTs (Dose Limiting Toxicities) during Cycle 1

Part 2 (Dose Expansion): Overall Response Rate (ORR)

Secondary outcome measures

Part 1 (Dose Escalation): Best Overall Response (BOR)/Progression Free Survival (PFS)

Part 2 (Dose Expansion): Overall CR/CRi rate

Part 2: Assessment of Safety and Tolerability via Clinical Measurements

+2 more

Trial Design

12Treatment groups

Experimental Treatment

Group I: TL-895 900 mg QD in R/R ParticipantsExperimental Treatment1 Intervention

Participants received TL-895 900 mg PiC orally QD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.

Group II: TL-895 80/160 mg QD in R/R ParticipantsExperimental Treatment1 Intervention

Participants received TL-895 80 mg powder in capsule (PiC) orally once daily (OD) for 3 days followed by TL-895 160 mg OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.

Group III: TL-895 600 mg QD in R/R ParticipantsExperimental Treatment1 Intervention

Participants received TL-895 600 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.

Group IV: TL-895 300 mg QD in R/R ParticipantsExperimental Treatment1 Intervention

Participants received TL-895 300 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.

Group V: TL-895 300 mg BID in R/R ParticipantsExperimental Treatment1 Intervention

Participants received TL-895 300 mg PiC orally twice daily (BID) in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.

Group VI: TL-895 150 mg BID in Treatment Naïve ParticipantsExperimental Treatment1 Intervention

Participants received TL-895 150 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.

Group VII: TL-895 150 mg BID in R/R ParticipantsExperimental Treatment1 Intervention

Participants received TL-895 150 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.

Group VIII: TL-895 150 mg BID & navtemadlin 240mg QD in Treatment Naïve Participants without 17p(del)Experimental Treatment2 Interventions

Participants received navtemadlin 240 mg administered QD on Days 1-7 in combination with TL-895 150 mg BID orally with food for 28 days with in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.

Group IX: TL-895 150 mg BID & navtemadlin 240mg QD in R/R Participants without 17p(del)Experimental Treatment2 Interventions

Group X: TL-895 150 mg BID & navtemadlin 240mg QD in R/R Participants with 17p(del)Experimental Treatment2 Interventions

Group XI: TL-895 100 mg BID in Treatment Naïve ParticipantsExperimental Treatment1 Intervention

Participants received TL-895 100 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.

Group XII: TL-895 100 mg BID in R/R ParticipantsExperimental Treatment1 Intervention

Participants received TL-895 100 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

TL-895

2020

Completed Phase 1

~10

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Telios Pharma, Inc.Lead Sponsor

9 Previous Clinical Trials

1,277 Total Patients Enrolled

Media Library

Navtemadlin (Other) Clinical Trial Eligibility Overview. Trial Name: NCT02825836 — Phase 1 & 2

B Cell Malignancies Research Study Groups: TL-895 150 mg BID in Treatment Naïve Participants, TL-895 150 mg BID & navtemadlin 240mg QD in R/R Participants with 17p(del), TL-895 150 mg BID in R/R Participants, TL-895 100 mg BID in R/R Participants, TL-895 100 mg BID in Treatment Naïve Participants, TL-895 80/160 mg QD in R/R Participants, TL-895 300 mg QD in R/R Participants, TL-895 600 mg QD in R/R Participants, TL-895 300 mg BID in R/R Participants, TL-895 900 mg QD in R/R Participants, TL-895 150 mg BID & navtemadlin 240mg QD in R/R Participants without 17p(del), TL-895 150 mg BID & navtemadlin 240mg QD in Treatment Naïve Participants without 17p(del)

B Cell Malignancies Clinical Trial 2023: Navtemadlin Highlights & Side Effects. Trial Name: NCT02825836 — Phase 1 & 2

Navtemadlin (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02825836 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there currently any opportunities to join this clinical research?

"Currently, the clinical trial in question is not enlisting new participants. This medical study was created on August 26th 2016 and last modified October 11th 2022. Despite this, there are still 5077 other trials seeking enrolment right now."

Answered by AI

What objectives are being pursued through this research endeavor?

"This ongoing study is attempting to evaluate the Dose Limiting Toxicities (DLTs) during Cycle 1. Secondary objectives include tracking Treatment-Emergent Adverse Events (TEAEs), Best Overall Response (BOR)/Progression Free Survival (PFS), and Duration of Clinical Response (DOR). These results will be monitored from Baseline up until two years after recruitment has concluded."

Answered by AI

Recent research and studies

Leukemia & LymphomaJournal

Phase I, First-in-human Trial of Bruton’s Tyrosine Kinase Inhibitor M7583 in Patients with B-cell Malignancies

Jurczak, Wojciech, Simon Rule, William Townsend, David Tucker, Barbara Sarholz, Jürgen Scheele, Martin Dyroff, John G. Gribben, Monika Długosz-Danecka, and Pier Luigi Zinzani. 2021. “Phase I, First-in-human Trial of Bruton’s Tyrosine Kinase Inhibitor M7583 in Patients with B-cell Malignancies”. Leukemia & Lymphoma. Informa UK Limited. doi:10.1080/10428194.2021.1913139.

clinicaltrials.govStudy

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

2016. "Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02825836.

All > Mantle Cell Lymphoma